This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mirza, I. Articles by Hsi, E. D. Search for Related Content PubMed PubMed Citation Articles by Mirza, I. Articles by Hsi, E. D. Social Bookmarking                            What's this?

Primary Cutaneous Follicular Lymphoma: An Assessment of Clinical, Histopathologic, Immunophenotypic, and Molecular Features

From the Cleveland Clinic Foundation, Cleveland, OH; British Columbia Cancer Agency, Victoria and Vancouver, British Columbia, Canada; and University of Michigan, Ann Arbor, MI.

Address reprint requests to Eric Hsi, MD, Department of Clinical Pathology, L-1, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195; email: ehsi{at}ccf.org

PURPOSE: Unlike nodal follicular lymphoma (NFL), Primary cutaneous follicular lymphomas (PCFLs) rarely express Bcl-2 protein or t(14;18)(q32;q21) (Bcl-2/IgH). The aim of this study was to further characterize PCFL in a large series from North America.

PATIENTS AND METHODS: Clinical data and archival formalin-fixed, paraffin-embedded tissue were obtained from 32 patients. PCFL was defined as follicular lymphoma limited to the skin at the time of diagnosis and within the first 6 months after diagnosis. Specimens were analyzed for the expression of CD3, CD10, CD20, Bcl-2, and Bcl-6 proteins by immunohistochemistry as well as for the presence of t(14;18)(q32;q21) by polymerase chain reaction.

RESULTS: The male-to-female ratio was 1.5:1, with a median age of 60 years. Twenty-four patients had lesions on the head and neck, five had lesions on the trunk, and three had lesions on both head and trunk. Follow-up data were available in all cases, with a mean length of 35.8 months. The majority of the patients were treated with radiation therapy. All patients were alive at last follow-up except one. Recurrence was noted in seven patients (22%), after a mean disease-free survival time of 17.7 months. CD10 and Bcl-6 expression were seen in 29 (91%) of 32 and 31 (97%) of 32 cases, respectively. Bcl-2 expression was noted in 13 (41%) of 32 cases. PCR results for t(14;18)(q32;q21) were positive in 11 (34%) of 32 patients and showed correlation with Bcl-2 protein expression. The sequencing of the t(14;18)(q32;q21) amplicons confirmed unique breakpoints in each of the seven tested cases. Comparison between the Bcl-2 and/or t(14;18)(q32;q21)-positive and t(14;18)(q32;q21)-negative cases revealed no significant difference in age, site, clinical course, or outcome.

CONCLUSION: We demonstrated Bcl-2 protein expression and t(14;18)(q32;q21) in a significant minority of cases, suggesting a relationship with NFL. It remains to be seen whether, on longer follow-up, there is any clinical difference in cases with and without t(14;18)(q32;q21).

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P. T. Bradford, S. S. Devesa, W. F. Anderson, and J. R. Toro Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases Blood, May 21, 2009; 113(21): 5064 - 5073. [Abstract] [Full Text] [PDF]

				K. Sentani, A. M. Maeshima, J. Nomoto, D. Maruyama, S.-W. Kim, T. Watanabe, Y. Kobayashi, K. Tobinai, and Y. Matsuno Follicular Lymphoma of the Duodenum: A Clinicopathologic Analysis of 26 Cases Jpn. J. Clin. Oncol., August 7, 2008; (2008) hyn069v1. [Abstract] [Full Text] [PDF]

				O. K. Weinberg, W. Z. Ai, M. R. Mariappan, C. Shum, R. Levy, and D. A. Arber ''Minor'' BCL2 Breakpoints in Follicular Lymphoma: Frequency and Correlation with Grade and Disease Presentation in 236 Cases J. Mol. Diagn., September 1, 2007; 9(4): 530 - 537. [Abstract] [Full Text] [PDF]

				B. D. Smith, G. L. Smith, D. L. Cooper, and L. D. Wilson The Cutaneous B-Cell Lymphoma Prognostic Index: A Novel Prognostic Index Derived From a Population-Based Registry J. Clin. Oncol., May 20, 2005; 23(15): 3390 - 3395. [Abstract] [Full Text] [PDF]

				R. Willemze, E. S. Jaffe, G. Burg, L. Cerroni, E. Berti, S. H. Swerdlow, E. Ralfkiaer, S. Chimenti, J. L. Diaz-Perez, L. M. Duncan, et al. WHO-EORTC classification for cutaneous lymphomas Blood, May 15, 2005; 105(10): 3768 - 3785. [Abstract] [Full Text] [PDF]

				B. D. Smith, E. J. Glusac, J. M. McNiff, G. L. Smith, P. W. Heald, D. L. Cooper, and L. D. Wilson Primary Cutaneous B-Cell Lymphoma Treated With Radiotherapy: A Comparison of the European Organization for Research and Treatment of Cancer and the WHO Classification Systems J. Clin. Oncol., February 15, 2004; 22(4): 634 - 639. [Abstract] [Full Text] [PDF]

				J. M. Connors, E. D. Hsi, and F. M. Foss Lymphoma of the Skin Hematology, January 1, 2002; 2002(1): 263 - 282. [Abstract] [Full Text]